- Market Research
- Stocks Research
- ETF Research
- Mutual Funds Research
- Options Research
- Bonds & Fixed Income Research
Stock Research
Stock Quotes & Research Tools
View our stock quotes and sample our research offering.
Try our powerful stock tools to help compare investments and get ideas.
Find out about our industry leading research providers.
| Last Price | Today's Change | Today's Volume |
|---|---|---|
| $149.61 | +1.75 (1.18%) | 2,744,752Above Average |
Details | |
|---|---|
| Today's Open | $140.10 |
| Previous Close | $147.86 |
| Day's Range | $138.00 - $154.44 |
| 52 Week range | $110.04 - $185.00 |
| Beta | 0.10 |
| Avg. Volume (10 Day) | 1,393,004 |
| Put/Call Ratio (1 Day) | 2.4 |
| Put/Call Ratio (30 Day) | 2.8 |
Dividends | |
|---|---|
BIIB does not currently pay a dividend. |
Shares | |
|---|---|
| Market Capitalization (Mid Cap) | $21.7B |
| Shares Outstanding | 146.6M |
| Shares Held By Institutions | 91% |
- 3:12 PM ETReuters
(Adds CEO comment in paragraph 4, shares in paragraph 5)Oct 30 (Reuters) - Biogen beat Wall...
- 2:55 PM ETReuters
(Corrects period in paragraph 11 to third quarter from secondquarter)Oct 30 (Reuters) - Biogen cut...
- 6:40 AM ETReuters
Oct 30 (Reuters) - :* BIOGEN OUTLOOK 2025 TOTAL REVENUE TO BE ABOUT FLAT TOINCREASING1%, AT CONSTANT...
- 6:22 AM ETReuters
Overview * Biogen Q3 2025 revenue of $2.5 bln beats analyst expectations * Adjusted EPS of $4.81...
- 6:03 AM ETReuters
Oct 30 (Reuters) - Biogen cut its annual profitforecast on Thursday, as it expects to take a hit of...
- UPDATE 1-Biogen tops quarterly profit estimates, eyes deals to build early-stage pipeline
- CORRECTED-Biogen trims annual profit forecast on expected hit from R&D-related charges
- BRIEF-Biogen Expects 2025 Total Revenue About Flat To Increasing 1%, At Constant Currency
- Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
- Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
- LEQEMBI� IQLIK�(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME�s �Best Inventions of 2025�
- Form 10-Q BIOGEN INC. For: Sep 30
- Form 8-K BIOGEN INC. For: Oct 30
- Form 8-K BIOGEN INC. For: Oct 14
View the rationale behind our Schwab Equity Rating with details on what factors and components contribute to the overall rating.
Qualitative analysis on Morningstar’s global equity coverage. Analyst commentary, star ratings and economic moat evaluations.
This report contains the Argus rating and qualitative assessment of a stock's investment potential.
CFRA's Stock Reports contain equity analysis covering 5,000 publicly traded companies. The reports provide CFRA's ranking and qualitative opinion, financial statistics, and up to 10 years of summary balance sheet and income statement data.
Detailed financials and consensus ratings from Refinitiv.
Manage market risk with quantitative technical analysis models from Market Edge.
Quotes are delayed by at least 15 minutes. Before trading, please check a real-time quote for current information.
Important Disclosures
Schwab Equity Ratings and other materials are for informational purposes only and is not an offer to sell or the solicitation of an offer to buy. Schwab Equity Ratings and the general buy/sell/hold guidance are not personal recommendations for any particular investor or client and do not take into account the financial, investment or other objectives or needs of, and may not be suitable for any particular investor or client. Before buying, investors and clients should consider whether the investment is suitable. Investors and clients should consider Schwab Equity Ratings as only a single factor in making their investment decision while taking into account the current market environment.
Schwab Equity Ratings utilize third-party data in the forming of a rating. Data is obtained from what are considered reliable sources; however, its accuracy, completeness or reliability cannot be guaranteed. Schwab Equity Ratings are generally updated weekly, so you should review and consider any recent market or company news before taking any action. Stocks may go down as well as up and investors (including clients) may lose money, including their original investment. Past performance is no indication of future results and returns are not guaranteed. For individualized advice, please contact Schwab at 1 (877) 284-9817. Note: An asterisk (*) next to a Schwab Equity Rating means that a potentially significant even has been announced for an A or B rated stock, Although Schwab generally does not monitor C, D, and F rated stocks for current news, from time to time, asterisks may appear on a particular stock due to certain circumstances (e.g. the downgrade of a stock from a B to C rating).
The news sources used on Schwab.com come from independent third parties. Schwab is not affiliated with any of the news content providers. Schwab is not responsible for the content, and does not write or control which particular article appears on its website. The securities markets (1) reserve all rights to the market data that they make available; (2) do not guarantee that data; and (3) shall not be liable for any loss due either to their negligence or to any cause beyond their reasonable control.